Elyse Stock
Director/Miembro de la Junta en Areteia Therapeutics, Inc. .
Cargos activos de Elyse Stock
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Areteia Therapeutics, Inc.
Areteia Therapeutics, Inc. BiotechnologyHealth Technology Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials. | Director/Miembro de la Junta | 17/04/2023 | - |
Historial de carrera de Elyse Stock
Antiguos cargos conocidos de Elyse Stock.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Director/Miembro de la Junta | - | 03/10/2022 |
Director Técnico/Científico/I+D | 01/08/2019 | 03/10/2022 | |
Corporate Officer/Principal | 21/06/2017 | 01/08/2019 |
Formación de Elyse Stock.
New York University School of Medicine | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 3 |
Operativa
Director/Board Member | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Corporate Officer/Principal | 1 |
Sectorial
Health Technology | 3 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Biohaven Pharmaceutical Holding Co. Ltd.
Biohaven Pharmaceutical Holding Co. Ltd. Pharmaceuticals: MajorHealth Technology Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. | Health Technology |
Areteia Therapeutics, Inc.
Areteia Therapeutics, Inc. BiotechnologyHealth Technology Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials. | Health Technology |
- Bolsa de valores
- Insiders
- Elyse Stock
- Experiencia